An observational study in Psoriasis, Atopic Dermatitis and Vitiligo, sponsored by Fondazione ISIDE. Not yet recruiting at 1 site in Italy. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Fondazione ISIDE · Observational
Among 104 studies in Psoriasis with a site in Italy — 14 open to participants now, 20 under way, 9 of them phase 3. Psoriasis · Italy.
Among the 104 studies in Psoriasis with a site in Italy, this one has the largest planned enrollment of the 24 observational ones that give a count, is one of 4 that started in 2026, is one of 24 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 102nd registered.
2,030 studies on the registry are indexed under Psoriasis; 277 are open to participants now.
Browse Psoriasis studies →14 of the 104 studies in Psoriasis with a site in Italy are open now. Recruiting first, the newest first:
ICIM International S.r.l. · Sites in Italy
Ages 18–65
ICIM International S.r.l. · Sites in Italy
Ages 18–65
Wooshin Labottach Co., Ltd. · Sites in Italy
Ages 18+
Takeda · Sites in Italy, United States, China and 4 more countries
Ages 4–17
Bristol-Myers Squibb · Sites in Italy, United States, Argentina and 13 more countries
Ages 12–17
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 199 across 407 observational studies indexed under Psoriasis.
Median enrollment 283 across the 80 interventional studies, 192 across the 24 observational. Of the 78 that completed or were terminated, 45 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 104 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Fondazione ISIDE as lead sponsor.
Fondazione ISIDE has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
5 of the studies in Psoriasis with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029516Phase 3Wooshin Labottach Co., Ltd.Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis | 2026-11 |
| NCT07545902ICIM International S.r.l.Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis | 2026-11-25 |
| NCT07546032ICIM International S.r.l.Clinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy | 2027-02-08 |
| NCT07256015Bristol-Myers SquibbDeucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | 2027-07-05 |
| NCT03886246LEO PharmaEffisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 104 studies in Psoriasis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12 years and older with psoriasis, atopic dermatitis, vitiligo, alopecia areata, or hidradenitis suppurativa.
LANDSCAPE is a non-interventional, multicenter, retrospective disease registry based on routinely collected clinical data (electronic health records and available medical documentation) from participating Italian centers. Data will cover the period January 2016 to December 2025. The registry will support real-world evaluation of treatment patterns, effectiveness and safety outcomes, disease severity scores, persistence/switching, and associated comorbidities across psoriasis, atopic dermatitis, vitiligo, alopecia areata, and hidradenitis suppurativa. Data will be pseudonymized prior to entry into the EDC system. Patients who exercise the opt-out right will not be included.
Patients with inflammatory skin diseases (psoriasis, atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa) followed at approximately 25 dermatology centers across Italy. The study population reflects real-world clinical practice, including patients managed in both academic and community dermatology settings within the Italian National Health Service (Servizio Sanitario Nazionale). Data are extracted retrospectively from routine medical records.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients (≥18 years) diagnosed with moderate-to-severe psoriasis according to clinical criteria, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Drug: Conventional Systemic Therapies · Drug: Biologic Therapies
Adult patients (≥18 years) diagnosed with moderate-to-severe atopic dermatitis, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Drug: Conventional Systemic Therapies · Drug: Biologic Therapies
Adult patients (≥18 years) diagnosed with alopecia areata, treated with systemic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Drug: Conventional Systemic Therapies · Drug: Biologic Therapies
Adult patients (≥18 years) diagnosed with vitiligo, treated at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records.
Drug: Conventional Systemic Therapies · Drug: Biologic Therapies
Adult patients (≥18 years) diagnosed with hidradenitis suppurativa, treated with systemic conventional and/or biologic therapies at participating Italian dermatology centers. No intervention is administered; data are collected retrospectively from medical records
Drug: Conventional Systemic Therapies · Drug: Biologic Therapies
Retrospective observation of conventional systemic treatments prescribed in routine clinical practice, including but not limited to methotrexate, cyclosporine, acitretin, and other conventional agents. No drugs are administered as part of this study; treatment data are collected from existing medical records.
Retrospective observation of biologic treatments prescribed in routine clinical practice, including but not limited to TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-4/IL-13 inhibitors, and JAK inhibitors. No drugs are administered as part of this study; treatment data are collected from existing medical records.
Patient Distribution by Disease Type
Number and proportion of patients in each disease cohort (psoriasis, atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa).
Time frame: January 2016 to December 2025
Age at Treatment Initiation
Mean age (years) at first systemic treatment initiation, reported by disease cohort.
Time frame: January 2016 to December 2025
Sex Distribution
Proportion of male and female patients (percentage) by disease cohort.
Time frame: January 2016 to December 2025
Treatment Patterns and Therapeutic Sequences
Description of systemic treatment utilization patterns, including conventional and biologic therapies, lines of therapy, treatment switches, and reasons for discontinuation.
Time frame: January 2016 to December 2025
Disease Severity Assessment Over Time
Evaluation of disease severity measures as recorded in routine clinical practice, including PASI for psoriasis, EASI/IGA for atopic dermatitis, SALT for alopecia areata, and Hurley staging for hidradenitis suppurativa.
Time frame: January 2016 to December 2025
Treatment Persistence and Drug Survival
Analysis of treatment duration and persistence rates for systemic therapies in real-world clinical practice
Time frame: January 2016 to December 2025
Plan to share: Undecided — Individual participant data will not be shared due to data protection requirements under GDPR (EU 2016/679) and Italian privacy legislation. Aggregate anonymized results will be published in peer-reviewed journals and presented at scientific conferences.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for May 2026, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.